GIAPREZA angiotensin ii Updated Nov 6
GIAPREZA has no upcoming FDA decision or pivotal readout; the next catalyst for Innoviva is the Q4 2026 earnings report (likely February 2027), where GIAPREZA's continued sales growth trajectory will be the key metric to watch. The drug's $23.1M quarterly run rate is on pace to help Innoviva hit its at-least-$150M full-year IST product sales guidance.
- GIAPREZA is the first and only FDA-approved synthetic angiotensin II vasopressor, giving it a unique mechanism in the septic-shock treatment algorithm as an add-on when traditional vasopressors like norepinephrine fail.
- U.S. net product sales of GIAPREZA reached $23.1 million in Q3 2026, contributing to 45% year-over-year growth in Innoviva's IST platform, which is on track to hit at least $150 million in full-year 2026 sales.
- Innoviva acquired the drug for just $149M in 2022 and has successfully grown sales; at the current quarterly run rate, GIAPREZA alone is on pace for ~$85-90M in annualized U.S. sales, representing a strong return on the acquisition cost.
- GIAPREZA competes in the ICU vasopressor market against cheap, established generics like norepinephrine and vasopressin, limiting its pricing power and adoption to refractory cases only.
- The drug was originally a laggard under La Jolla (prompting the $149M fire sale to Innoviva in 2022), and while sales have grown under Innoviva, the addressable market is narrow (refractory septic shock patients).
- Patent protection is estimated to expire around 2031-2037, and with 11 Orange Book patents, generic entry remains a long-term overhang.